

## **Clinical Policy: Dalteparin (Fragmin)**

Reference Number: CP.PHAR.225

Effective Date: 05.01.16

Last Review Date: 02.18

Line of Business: Commercial, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Dalteparin (Fragmin<sup>®</sup>) is a low molecular weight heparin (LMWH).

### **FDA Approved Indication(s)**

Fragmin is indicated:

- For prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy;
- For prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):
  - In patients undergoing hip replacement surgery;
  - In patients undergoing abdominal surgery who are at risk for thromboembolic complications;
  - In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness;
- For extended treatment of symptomatic venous thromboembolism (VTE: proximal DVT and/or PE), to reduce the recurrence of VTE in patients with cancer. In these patients, the Fragmin therapy begins with the initial VTE treatment and continues for six months.

Limitation(s) of use: Fragmin is not indicated for the acute treatment of VTE.

### **Policy/Criteria**

Provider *must* submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Fragmin is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Thrombosis/Thromboembolism\*** (must meet all):

1. Any of the following indications (a, b or c):
  - a. Thrombosis or thromboembolism prevention associated with any of the following conditions:
    - i. Cancer;
    - ii. Unstable angina or myocardial infarction;
    - iii. Atrial fibrillation or prosthetic heart valve;
    - iv. Major surgery - orthopedic and non-orthopedic;
    - v. Critical illness related to ICU admissions or events;

**CLINICAL POLICY****Dalteparin**

- vi. Restricted mobility associated with acute illnesses or conditions;
- vii. Implanted devices-vascular (e.g., central venous access device, umbilical venous catheter, devices/fistulas related to hemodialysis, ventricular assist devices);
- b. Thrombosis or thromboembolism treatment;
- c. Short-term prophylaxis for transition to or from oral anticoagulation;
- 2. Failure of a trial of enoxaparin unless (a, b or c):
  - a. Enoxaparin is contraindicated;
  - b. History of clinically significant adverse effects to enoxaparin;
  - c. The requested use is FDA labeled for dalteparin but not for enoxaparin (i.e., VTE treatment in patients with cancer).

**Approval duration:****Medicaid** - 6 months**Commercial** – Length of Benefit

---

*\*Includes off-label use for adults and pediatrics.*

**B. Anticoagulation in Pregnancy: Ante- and Postpartum (off-label) (must meet all):**

- 1. Any of the following indications:
  - a. Acute venous thrombosis during current pregnancy;
  - b. Prior venous thrombosis;
  - c. Receiving long-term therapy with a vitamin K antagonist (e.g., warfarin);
  - d. Prosthetic heart valve;
  - e. Inherited thrombophilia;
  - f. Antiphospholipid antibody syndrome;
  - g. Development of severe ovarian hyperstimulation syndrome post assisted reproduction;
  - h. Cesarean section – current pregnancy and request is for the postpartum period.
  - i. Any other indication not listed here that is listed in section I.A.
- 2. Member is pregnant or < 6 months postpartum;
- 3. Failure of a trial of enoxaparin unless contraindicated or clinically significant adverse effects are experienced.

**Approval duration:****Medicaid** – Antepartum (to estimated delivery date); postpartum (6 months)**Commercial** – Length of Benefit**C. Other diagnoses/indications**

- 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

**II. Continued Therapy****A. Thrombosis/Thromboembolism (must meet all):**

- 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

**CLINICAL POLICY****Dalteparin**

2. Member is responding positively to therapy;
3. Continued use is limited to any of the following indications (a, b or c):
  - a. Venous thrombosis prophylaxis or treatment in the presence of cancer;
  - b. Past history of failed anticoagulation therapy (clot development) on a non-LMWH\* (e.g., failed therapy on heparin, fondaparinux, warfarin, apixaban, dabigatran, edoxaban, rivaroxaban);
  - c. Any other indication in section I.A where bridging to warfarin is inappropriate or member has a contraindication to warfarin and extended (indefinite duration) anticoagulation therapy is required.

**Approval duration:****Medicaid** - 6 months**Commercial** – Length of Benefit

---

*\*LMWHs include enoxaparin and dalteparin.*

**B. Anticoagulation in Pregnancy: Ante- and Postpartum (off-label) (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. See Section II.A for continued anticoagulation therapy beyond 6 months postpartum.

**Approval duration:****Medicaid** – Antepartum (to estimated delivery date); postpartum (6 months)**Commercial** – Length of Benefit**C. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less); or**

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 or evidence of coverage documents.

**IV. Appendices/General Information***Appendix A: Abbreviation/Acronym Key*

DVT: deep vein thrombosis

LMWH: low molecular weight heparin

PE: pulmonary embolism

STEMI: ST-elevated myocardial infarction

VTE: venous thromboembolism (typically refers to DVT or PE)

**CLINICAL POLICY**

**Dalteparin**

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
enoxaparin (Lovenox®) - Adults	DVT prophylaxis in abdominal surgery 40 mg SC once daily DVT prophylaxis in knee replacement surgery 30 mg SC every 12 hours DVT prophylaxis in hip replacement surgery 30 mg SC every 12 hours or 40 mg SC once daily DVT prophylaxis in medical patients 40 mg SC once daily Inpatient treatment or acute DVT with or without PE 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily Outpatient treatment of acute DVT without PI 1 mg/kg SC every 12 hours Unstable angina and non-Q wave MI 1 mg/kg SC every 12 hours (with aspirin) Acute STEMI in patient < 75 years of age 30 mg single IV bolus plus a 1 mg/kg SC dose followed by 1 mg/kg SC every 12 hours (with aspirin) Acute STEMI in patient ≥ 75 years of age 0.75 mg/kg SC every 12 hours (no bolus) (with aspirin)	Dose as specified; duration may vary.

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

**V. Dosage and Administration**

<b>Indication</b>	<b>Dosing Regimen</b>	<b>Maximum Dose</b>
<b>Adults</b>		
Unstable angina and non-Q-wave MI	120 IU/kg SC every 12 hours (with aspirin)	Varies
DVT prophylaxis in abdominal surgery	2,500 IU SC once daily or 5,000 IU SC once daily or 2,500 IU SC followed by 2,500 IU SC 12 hours later and then 5,000 IU SC once daily	
DVT prophylaxis in hip replacement surgery	Postoperative start – 2,500 IU SC 4 to 8 hours after surgery, then 5,000 IU SC once daily or Preoperative start – day of surgery 2,500 IU SC 2 hours before surgery followed by 2,500 IU SC 4 to 8 hours	

**CLINICAL POLICY**

**Dalteparin**

Indication	Dosing Regimen	Maximum Dose
<b>Adults</b>		
	after surgery, then 5,000 IU SC once daily Preoperative start – evening before surgery 5,000 IU SC followed by 5,000 IU SC 4 to 8 hours after surgery	
DVT prophylaxis in medical patients	5,000 IU SC once daily	
Extended treatment of VTE in patients with cancer	Month 1: 200 IU/kg SC once daily Months 2 – 6: 150 IU/kg SC once daily	

**VI. Product Availability**

- Single-dose prefilled syringe: 2,500 IU/ 0.2 mL, 5,000 IU/ 0.2 mL, 7,500 IU/ 0.3 mL, 12,500 IU/ 0.5 mL, 15,000 IU/ 0.6 mL, 18,000 IU/ 0.72 mL
- Single-dose graduated syringe: 10,000 IU/ mL
- Multiple dose vial: 95,000 IU/3.8 mL

**VII. References**

1. Fragmin Prescribing Information. New York, NY: Pfizer, Inc.; June 2017. Available at <http://labeling.pfizer.com/ShowLabeling.aspx?id=2293>. Accessed October 2017.
2. Executive summary: Antithrombotic therapy and prevention of thrombosis: CHEST guidelines and expert panel reports. Available at <http://www.chestnet.org/Guidelines-and-Resources/CHEST-Guideline-Topic-Areas/Pulmonary-Vascular>. Accessed November 2017. *The CHEST guideline series presents recommendations for the prevention, diagnosis, and treatment of thrombosis, addressing a comprehensive list of clinical conditions, including medical, surgery, orthopedic surgery, atrial fibrillation, stroke, cardiovascular disease, pregnancy, and neonates and children.*
3. Thromboembolism in pregnancy. Practice Bulletin No. 123. American College of Obstetrics and Gynecologists. *Obstet Gynecol.* 2011; 118: 718-729.
4. Dalteparin. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at [nccn.org](http://nccn.org). Accessed October 2017.
5. Cancer-associated venous thromboembolic disease (Version 1.2017). In: National Comprehensive Cancer Network Clinical Practice Guidelines. Available at [nccn.org](http://nccn.org). Accessed October 2017.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1645	Injection, dalteparin sodium, per 2500 IU

Reviews, Revisions, and Approvals	Date	P&T Approval Date
<p>Policy combines Fragmin information from the CP.PHAR.04.LMWH policy and the CP.PHAR.45 Anticoagulant Therapy Pregnancy policy.</p> <p>Added indication for “Thromboembolic complications due to acute thromboembolic stroke with impaired mobility.” Added bridge to or contraindication to warfarin for DVT without PE.</p> <p>Added requirement for additional VTE risk factor for Cesarean section indication, as well as bridge to warfarin if anticoagulation therapy is required &gt; 6 weeks. Added an indication for receiving long-term therapy with a vitamin K antagonist per the Chest guidelines. Added continuation criteria for VTE in presence of cancer.</p>	04.16	05.16
<p>Section I.A. Criteria are edited to follow CHEST 2012 and 2016 guidelines in addition to labeled indications. Major additions include 1) prophylaxis: hip fracture/knee replacement, major orthopedic, general, cardiac, thoracic surgery, craniotomy; traumatic injury; critical illness; restricted mobility due to intracerebral hemorrhage; a-fib; prosthetic heart valve; 2) treatment: SVT; CVST; splanchnic thrombosis without cancer; nonbacterial thrombotic endocarditis. Warfarin bridging criteria are moved to renewal criteria. Safety information is removed. Removed section I.B. Required risk factors associated with Cesarean. Added preferencing for enoxaparin.</p> <p>Section II. Criteria are edited to follow CHEST 2016 guidelines. Major additions include 1) recurrent venous thrombosis on a non-low molecular weight heparin, 2) any other indication in section I.A., where bridging to warfarin is inappropriate or member has a contraindication to warfarin and extended (indefinite) anticoagulation therapy is required.</p>	04.17	05.17
<p>1Q18 annual review:</p> <ul style="list-style-type: none"> <li>- Combined policies for Medicaid and commercial lines of business</li> <li>- Section I.A., Venous Thrombosis, is changed to “Thrombosis and Thromboembolism” so as not to restrict to venous thrombi.</li> </ul> <p>Section I.A criteria are edited to encompass CHEST guidelines for neonates and children (seen primarily under implantable devices), and the criteria is collapsed to maximize consistency across the Lovenox, Fragmin and Arixtra policies.</p> <ul style="list-style-type: none"> <li>- Per specialist recommendation an additional indication is added for short-term prophylaxis to or from oral anticoagulation.</li> </ul> <p>Continuation criteria added for pregnancy.</p>	12.01.17	02.18

## CLINICAL POLICY

### Dalteparin

Reviews, Revisions, and Approvals	Date	P&T Approval Date
- References reviewed and updated.		

#### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.



**CLINICAL POLICY****Dalteparin**

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**For Health Insurance Marketplace members**, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.